Vinca Institute for Nuclear Sciences

What Vinca Institute for Nuclear Sciences does

Vinca Institute for Nuclear Sciences is a state scientific institute of national importance for the Republic of Serbia, operating under the University of Belgrade since its founding in 1948. It functions as a multidisciplinary nuclear research institution with operations across physics, chemistry, biology, and engineering-technological disciplines, anchored by dedicated laboratories (Nuclear and Plasma Physics; Radiation Chemistry and Physics; Radiation Protection; Thermal Engineering and Energetics) and operational centers (Motors and Vehicles; Radioisotopes; Permanent Education). Its core technology portfolio centers on radioisotope production and GMP-certified radiopharmaceutical manufacturing — including the Universal 99Mo/99mTc Generator (40 years of clinical use), 131I therapeutic capsules, 177Lu-labeled peptides for neuroendocrine tumor therapy, and an extensive kit portfolio of 99mTc radiopharmaceuticals (DPD, MIBI, DMSA, DTPA, MAA, Sn-colloid).

Name

Vinca Institute for Nuclear Sciences

Legal name

Institut za nuklearne nauke Vinča

Website

https://vin.bg.ac.rs

Company type

Private

Founded year

1948

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Vinca Institute for Nuclear Sciences is a Serbian state research institute, founded in 1948, producing GMP-certified radiopharmaceuticals, operating 18+ vehicle testing locations, and delivering accredited radiation protection and nuclear research services.

Ownership category

akta.pro rank

Product category

Nuclear Science Research and Radiopharmaceutical Manufacturing

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Irradiation Apparatus Manufacturing (334517), Testing Laboratories and Services (54138)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Radiation Safety, Dosimetry & Regulatory Compliance (Nuclear Medicine) (HLAIAGAJ)

Keywords

• Nuclear science research
• Radiopharmaceutical manufacturing
• Radiation protection services
• Vehicle testing certification
• Gamma radiation sterilization

Headquarters

HQ city

Vinça

HQ country

France

HQ region

Europe

Offices18 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

1. Radioisotope and Radiopharmaceutical Products: Production and sale of radiopharmaceuticals including 99Mo/99mTc generators, 131I capsules, and 177Lu-labeled peptides for diagnostic and therapeutic applications in nuclear medicine.
2. Vehicle and Motor Testing Services: Testing services for individually modified vehicles, ADR certification for dangerous goods transport, conformity control of new vehicles at multiple testing locations across Serbia.
3. Radiation Protection and Certification Services: Accredited laboratory services, certificates of conformity, radiation protection authorizations for various industries and applications.
4. Research Projects: National and international scientific research projects funded by Science Fund of Republic of Serbia, IAEA, HORIZON, and bilateral cooperation programs.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Vinca Institute is a state-owned nuclear sciences research institute that develops, produces and supplies GMP-certified radiopharmaceuticals (99Mo/99mTc generators, 131I capsules, 177Lu-labeled peptides and 99mTc radiopharmaceutical kits) to clinical centers, while also operating a network of 18+ vehicle testing and certification centers, accredited radiation protection and calibration laboratories, industrial gamma sterilization services, and professional training programs for radiation safety and non-destructive testing.

Product overview

Vinca Institute for Nuclear Sciences operates as a multidisciplinary nuclear research institution offering a portfolio of radioisotope products and industrial services. The core product portfolio includes radiopharmaceuticals produced by the Radioisotope Laboratory—featuring the 99Mo/99mTc Generator (celebrating 40 years of clinical use), 131I therapeutic capsules, 177Lu-labeled peptides for neuroendocrine tumor therapy, and multiple radiopharmaceutical kits for 99mTc preparation. Industrial services encompass vehicle testing and certification (Center for Motors and Vehicles), radiation source replacement and transport, and gamma radiation sterilization. Educational offerings include professional training courses in radiation protection, non-destructive testing, and explosion protection through the Center for Permanent Education. The institution serves clinical centers across Serbia and Republic of Srpska, industrial clients, and provides regulatory-compliant services under various licenses and accreditations.

Differentiator

Problem solved

Functional benefit

Products and services

• 99Mo/99mTc Universal Generator

Quantifiable outcome

• 40 years of successful clinical application of radiopharmaceutical products
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Faculty of Technical SciencescoreStrategic or Co-development Partner · 1 July 2026Memorandum of Understanding signed between Vinca Institute and Faculty of Technical Sciences for joint research and academic cooperation.
• Monastery HilandarcoreStrategic or Co-development Partner · 15 October 2025Scientific and professional cooperation agreement signed between Vinca Institute and Monastery Hilandar for collaborative research and knowledge exchange.
• Institute of Technical Sciences SANUminorStrategic or Co-development PartnerPartner institution in PRIZMA project WaPoDe (Water Pollutants Detection) - water pollutant detection using ZnO-modified electrochemical sensors.
• CONVINCE CenterminorStrategic or Co-development PartnerJoint center for synthesis, modification and characterization of materials for hydrogen energy and renewable energy sources. Accreditation process ongoing.
• Institut tehničkih nauka SANUminorStrategic or Co-development PartnerProject holder for RadioMag project on radioactive magnetic nanoconstructs for tumor therapy.
• Tehnicki fakultet u BoruminorStrategic or Co-development PartnerPartner institution for ASPIRE project on low-dimensional nanomaterials for energy storage and sensing applications.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Others

• TÜV SÜD: Global testing, inspection and certification body. Comparable to Vinča's accredited vehicle testing, radiation protection certification and ISO-accredited laboratory services.

Emerging players

• Telix Pharmaceuticals: Commercial-stage theranostics company developing Lu-177 and other targeted radionuclide therapies for oncology. Comparable to Vinča's 177Lu-labeled peptide and RadioMag therapeutic programs.

Broad incumbents

• Nordion (Sotera Health): Major global supplier of medical isotopes including Mo-99 and other radioisotopes, plus gamma sterilization services. Comparable to Vinča's radioisotope production and gamma sterilization facility.
• Advanced Accelerator Applications (Novartis): Novartis-owned radioligand therapy leader (Lutathera, Pluvicto) using Lu-177 peptides. Operates at much larger scale but directly comparable therapeutic modality to Vinča's 177Lu program.
• GE HealthCare: Global medical imaging and radiopharmaceutical company with broad product lines including Tc-99m generators and PET tracers. Overlaps with Vinča's nuclear medicine and diagnostic imaging reagent offering.

Direct peers

• Lantheus Holdings: Specialized radiopharmaceutical company focused on diagnostic and therapeutic nuclear medicine agents, including Tc-99m-based products. Closely comparable to Vinča's therapeutic and diagnostic isotope portfolio.
• Curium Pharma: One of the largest global manufacturers of radiopharmaceuticals and nuclear medicine products, including Mo-99/Tc-99m generators and therapeutic isotopes. Directly comparable to Vinča's Radioisotope Laboratory product portfolio.
• IBA (Ion Beam Applications): Designs and manufactures cyclotrons, radiopharma production systems and provides radioisotope production solutions. Comparable on the technology/production infrastructure side to Vinča's nuclear and plasma physics capabilities.
• Eckert & Ziegler Strahlen- und Medizintechnik: Produces radioactive isotopes, sealed sources and radiopharmaceutical components for medical and industrial use. Comparable to Vinča's closed radiation source production and radiopharma activities.

Regional players

• CERIC-ERIC: Central European Research Infrastructure Consortium offering multi-disciplinary analytical techniques using ion beams and complementary methods. Comparable as a publicly-funded, multi-country European research infrastructure peer to Vinča's regional nuclear science mandate.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vinca-institute-of-nuclear-sciences
• Facebookfacebook.com/profile.php

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vinca Institute for Nuclear Sciences